Effect of smoking status on the efficacy of the SMART regimen in high risk asthma by Pilcher, Janine et al.
1 
 
THE EFFECT OF SMOKING STATUS ON THE EFFICACY OF THE SMART 
REGIMEN IN HIGH RISK ASTHMA 
1,2 *Janine Pilcher, BSc, MBChB, 1,2,3 *Mitesh Patel, BMedSci, BMBS, MRCP, PhD, 
4Helen K Reddel, MBBS, PhD 
1Alison Pritchard, 5Peter Black MBChB, FRACP (deceased), 3Dominick Shaw MD, 
FRCP, 
6Shaun Holt, MBChB, 
2,7Mark Weatherall, MBChB, FRACP,  1,2Richard Beasley, MBChB, DSc, 
1Medical Research Institute of New Zealand, Wellington, New Zealand 
2Capital & Coast District Health Board, Wellington, New Zealand 
3Nottingham Respiratory Research Unit, School of Medicine,  
University of Nottingham, United Kingdom 
4Clinical Management Group, Woolcock Institute of Medical Research, University 
of Sydney, Australia 
5University of Auckland, Auckland, New Zealand 
6 Clinicanz, Tauranga, New Zealand 
7University of Otago, Wellington, New Zealand 
 
Word count: 2,565 (abstract 223)  
*JP and MP are joint first authors 
Correspondence: 
Janine Pilcher 
Medical Research Institute of New Zealand 
Level G, CSB Building, Wellington Hospital, 
Private Bag 7902, Wellington 6242, New Zealand 
Telephone: 64-4-805 0241, Fax: 64-4-389 5707 
Email: janine.pilcher@mrinz.ac.nz 
2 
 
 
SUMMARY AT A GLANCE (32 words) 
 
This study has shown that the favourable efficacy/safety profile of single 
combination ICS/LABA inhaler maintenance and reliever therapy regimen in adult 
patients with high risk asthma is not influenced by smoking status. 
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ABSTRACT (223 words) 
 
Background and objective: The optimal management of people with asthma with 
a significant smoking history is uncertain. The aim of this study was to determine 
whether the efficacy/safety profile of single combination inhaled corticosteroid/long 
acting beta-agonist inhaler maintenance and reliever therapy is influenced by 
smoking status. 
Methods: We undertook secondary analyses from an open-label 24-week 
randomised study of 303 high risk adult asthma patients randomised to 
budesonide/formoterol 200-6µg metered dose inhaler for maintenance (2 actuations 
twice daily) and either budesonide/formoterol 200-6µg metered dose inhaler 1 
actuation (“SMART” regimen)  or salbutamol 100µg 1-2 actuations for symptom 
relief (“Standard” regimen).  Smoking status was classified in to three groups; as 
“current”, “ex” or “never” and a smoking/treatment interaction term tested for each 
outcome variable. The primary outcome variable was number of participants with at 
least one severe exacerbation. 
Results: There were 59 current, 97 ex and 147 never smokers included in the 
analyses. The smoking status/treatment interaction term was not statistically 
significant for any of the outcome measures. With adjustment for smoking status, 
the number of participants with severe exacerbations was lower with the SMART 
regimen (OR 0.45, 95% CI 0.26-0.77, P= 0.004; P value for interaction between 
smoking status and treatment 0.29). 
Conclusions: We conclude that the favourable safety/efficacy profile of the SMART 
regimen applies to patients with high risk asthma, irrespective of smoking status. 
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SHORT TITLE  
Smoking status and the SMART regimen 
 
ABBREVIATIONS 
ACQ: Asthma control questionnaire 
COPD: Chronic obstructive pulmonary disease 
ED: Emergency Department 
FEV1: forced expiratory volume in 1 second 
ICS: Inhaled corticosteroid 
LABA: Long acting beta-agonist 
MDI: Metered dose inhaler 
RCT: Randomised controlled trial 
SABA: Short acting beta- agonist 
SMART: Single maintenance and reliever therapy 
 
 
 
5 
 
 
INTRODUCTION 
 
The management of individuals with asthma who smoke is an important clinical 
priority.1,2  Cigarette smoking is associated with greater morbidity from asthma and 
a higher risk of severe exacerbations.3-5 Amongst individuals  with asthma, heavy 
smokers are at greater risk of asthma mortality compared with non smokers.6 The 
optimal management of asthmatics who smoke is uncertain. Large randomised 
controlled trials (RCTs) that inform asthma management guidelines generally 
exclude current smokers or ex smokers with at least a 10 year pack year history to 
avoid recruitment of patients with concomitant chronic obstructive pulmonary 
disease (COPD).7 Furthermore it is known that individuals with asthma who smoke 
benefit less from inhaled corticosteroid (ICS) and oral corticosteroid therapy in terms 
of symptoms, lung function, and risk of severe exacerbations.8-13     
 
In patients with severe asthma the use of a single combination ICS/fast-acting long-
acting beta-agonist (LABA) inhaler as both maintenance and reliever therapy, (the 
SMART regimen), leads to reduced risk of severe exacerbations compared with 
combination ICS/LABA inhaler as maintenance and short-acting beta-agonist 
(SABA) for reliever therapy.14-16 This is based on RCTs that did not report treatment 
effects in relation to smoking status.14-16 It is therefore uncertain if the favourable 
efficacy/safety profile of the SMART regimen can be generalised to patients with 
severe asthma who have important current or ex smoking histories.  The SMART 
regimen could have a greater relative benefit for smokers with asthma because the 
increased ICS dose may partially reverse the reduced ICS responsiveness.10 
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Alternatively, the SMART regimen may be less beneficial for smokers with asthma 
because of lesser efficacy from the increased use of ICS during worsening 
symptomatic asthma. Smokers with asthma may also have different responses to 
variable dosing of LABA and SABA therapy, compared to non smokers.   
 
In recognition of the potential role for smoking status in response to treatment, this 
study reports a secondary analysis investigating whether smoking affects the 
efficacy of the SMART regimen in a RCT of high risk adults with asthma, of whom 
51% were current or ex smokers.17 Our hypothesis was that current and ex smokers 
would have worse clinical outcomes than non smokers and lesser efficacy from the 
SMART regimen compared with non smokers. 
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METHODS 
Design  
This multicentre open-label study randomised 303 asthma patients to the SMART 
or the Standard therapy regimen.17 The study was approved by the New Zealand 
Multi-Region Ethics Committee and has the Australian and New Zealand Clinical 
Trials Registry number ACTRN12610000515099. Full written informed consent was 
required prior to study participation. 
 
Participants 
Participants were aged 16 to 65 years and had a current prescription for ICS with at 
least one asthma exacerbation (presentation to an Emergency Department (ED) or 
general practice resulting in a prescription for oral corticosteroids or treatment with 
spacer-delivered or nebulised bronchodilator, or self-administration of prednisone 
for asthma for at least 3 days) in the previous year.17 Exclusion criteria included a 
diagnosis of COPD or onset of respiratory symptoms after the age of 40 in current 
or ex smokers with a ≥10 pack year smoking history. The study protocol is available 
at http://www.mrinz.ac.nz/uploads/mrinz/SMART_Protocol.pdf.  
 
Interventions 
Participants were randomised 1:1 to receive either the SMART regimen, which was 
200/6 micrograms (mcg) budesonide/formoterol via metered dose inhaler (MDI) 
(Vannair, AstraZeneca Limited, Auckland, New Zealand; this is the MDI formulation 
of Symbicort Turbuhaler) for maintenance (two actuations twice daily) and one 
actuation as required for symptom relief, or the Standard regimen consisting 
200/6mcg budesonide/formoterol via MDI for maintenance (two actuations twice 
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daily) and 100mcg salbutamol via MDI (Ventolin, GlaxoSmithKline Limited, 
Auckland, New Zealand), 1-2 actuations as required for symptom relief.  At the first 
visit participants were given a written asthma self-management plans and inhaler 
technique was checked. Subsequent visits took place at weeks 3, 10, 17, and 24.  
 
The Smartinhaler Tracker (Nexus6 Limited, Auckland, New Zealand) electronic 
monitor was incorporated into all MDIs, and recorded the date and time of each 
actuation. Detailed trial quality control processes took place.18,19 Data were 
uploaded from the inhalers at each visit. 
 
Data analysis and study outcomes 
 
Data analysis was by intention to treat.  
 
The primary outcome variable was the number of participants with at least one 
severe exacerbation, according to the ATS/ERS Taskforce criteria: the use of 
systemic corticosteroids for at least 3 days, or admission to hospital or visit to the 
ED because of asthma that required systemic corticosteroids.20 High beta-agonist 
use was defined as >16 actuations of salbutamol in the Standard regimen and >12 
actuations of budesonide-formoterol for the SMART regimen (i.e. > eight actuations 
of budesonide/formoterol, additional to the four maintenance doses), in 24 hours. 
These definitions were based on self-management plan recommendations for beta-
agonist use requiring medical review,21, 22 and supported by the bronchodilator 
equivalence of 6mcg formoterol to 200mcg salbutamol with repeat dosing in acute 
asthma.23, 24 For the Standard regimen, marked and extreme beta-agonist overuse 
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were defined as >24 and >32 salbutamol actuations in 24 hours, respectively.  For 
the SMART regimen, marked and extreme overuse were defined as >16 and >20 
budesonide-formoterol actuations in 24 hours, respectively (i.e. >12 and >16 
actuations of budesonide/formoterol, additional to the four maintenance doses, 
respectively). 
 
Odds ratios for the risk of at least one severe exacerbation by randomised group, 
the primary outcome variable for this analysis, were estimated by logistic 
regression. Secondary outcome variables analysed by logistic regression were: at 
least one hospital or ED attendance; at least one day of: beta-agonist overuse, 
marked overuse, or extreme overuse; one or less budesonide/formoterol inhaler 
actuations per day; or no budesonide/formoterol inhaler actuations per day over the 
study period. Relative rates by Poisson regression, with an offset for the observation 
time, were used for the count variables including number of severe exacerbations 
and number of courses of oral corticosteroids; and number of days of high use, 
marked overuse, or extreme overuse, or with one or less budesonide/formoterol 
inhaler actuations per day or no budesonide/formoterol inhaler actuations per day. 
ANCOVA was used for differences on the logarithm transformed scale, where 
exponentiation is interpreted as mean ratios, for daily equivalent ICS use. Survival 
analysis for day to first exacerbation used Cox Proportional Hazards. Contingency 
table analysis was used for oral corticosteroid dose (prednisone equivalent per 
year) by creating four bands of use. For this outcome the pre-specified main RCT 
analysis plan was to seek an appropriate transformation for the dose, such as the 
logarithm transformation, or use a non-parametric method (the Mann-Whitney test), 
to compare the groups. After the data were collected many participants were found 
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to have no oral prednisone use so neither of these strategies was able to be used. 
The other continuous variables which had appropriate data distributions were 
analysed by ANCOVA: Forced expiratory volume in one second (FEV1), FEV1 
percentage predicted, Asthma control questionnaire-7 (ACQ-7). 
 
The general analysis strategy for the secondary analysis of the effect of smoking 
reported here was to test a smoking-treatment interaction term for each outcome 
variable. Smoking was classified as: “current smoker”, “ex smoker”, and “never 
smoker”. Participants reported which category they belonged to at the first study 
visit. Our analysis plan was to report the difference in outcome variables between 
SMART and Standard for current smokers compared to never smokers, and ex 
smokers compared to never smokers, if there was evidence of statistical 
significance, P<0.05, for an interaction between smoking and randomised 
treatment. Otherwise we planned to report the difference in outcome for current 
smokers versus never smokers, and ex smokers versus never smokers, adjusted 
for randomised treatment. In this case the lack of statistical evidence of an 
interaction would be consistent with the same relative effect of treatment for all 
smoking categories.  
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RESULTS 
Three hundred and three participants were enrolled between June 2010 and 
September 2011. Fifty nine (19%) were current smokers, 97 (32%) ex smokers and, 
147 (49%) were never smokers (Table 1, Figure 1). Current smokers had between 0.3 
and 44 pack years of smoking, and ex smokers between 0.2 and 60 pack years of 
smoking. Current smokers had higher ACQ-7 scores (i.e. worse asthma control) 
compared to ex and never smokers.  
 
SMART versus Standard regimen, with adjustment for smoking  
There was no evidence of interaction between smoking status and randomised 
treatment interaction term for any outcome measure. This means that the relative 
effect of randomised treatment was the same for participants with different smoking 
status (Tables 2 and 3).  
 
The outcomes by randomised treatment, adjusted for smoking status, are shown in 
Tables 2 and 3.  The proportion of participants with at least one severe exacerbation 
was lower in those randomised to the SMART regimen, with an odds ratio of 0.45 (95% 
CI 0.26 to 0.77), P= 0.004; P value for interaction between smoking status and 
treatment 0.29 (Table 2). 
 
After adjustment for smoking status, the number of severe exacerbations was lower in 
participants randomised to SMART (Table 2). There was no significant difference in 
the composite systemic corticosteroid exposure between the two regimens following 
adjustment for smoking status (Table 2). In addition, the ACQ-7 scores at visit 5 were 
lower in the SMART group, compared with Standard (Table 2). 
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After adjustment for smoking status, the SMART regimen was not associated with a 
significantly different proportion of participants with at least one episode of high, 
marked or extreme beta-agonist overuse when compared to the Standard regimen 
(Table 3). However, the SMART group had significantly fewer number of days of high 
use, marked overuse, extreme overuse, and number of days of high use without 
medical review within 48 hours (Table 3). The number of days of non-adherence to 
maintenance therapy was also lower in the SMART group (Table 3).  
 
Outcomes of smokers, ex smokers and never smokers, adjusted for treatment 
After adjustment for treatment regimen, smoking status was associated with an 
increased risk of at least one severe exacerbation, an increased number of severe 
exacerbations, an increased risk of at least one hospital admission or ED attendance, 
an increased number of courses of oral corticosteroids, and increased composite 
systemic corticosteroid exposure, compared with never smokers. For each of these 
outcomes there was a significant difference between ex smokers and never smokers, 
but no significant difference between current and never smokers (Table 4).  
 
After adjustment for treatment regimen, smoking status was associated with high, 
marked and extreme beta-agonist overuse, with current smokers and ex smokers 
having higher rates compared with never smokers (Table 5).  After adjustment for 
treatment regimen, smoking status was associated with overuse days without medical 
review and the number of days of no budesonide/formoterol actuations, with more 
days occurring in the current smokers compared to never smokers (Table 5).  
DISCUSSION 
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This study shows that the favourable efficacy/safety profile for the SMART regimen in 
high risk adults with asthma was similar regardless of smoking status. This suggests 
that the SMART regimen can be recommended in current and ex smokers, who 
represent a particularly high risk group. 
 
The broad inclusion criteria of this RCT ensured the findings are widely generalisable 
to patients with high risk asthma.  Fifty one percent of participants were current 
smokers or ex smokers, so we could robustly assess if the efficacy of the SMART 
regimen was influenced by smoking status. Our study complements the findings of an 
analysis of the influence of smoking status on response to two different maintenance 
dosing regimens for SMART with 200/6mcg of budesonide/formoterol, one versus two 
actuations twice daily.26 In that study there was a significantly greater reduction in 
severe exacerbations by use of two maintenance budesonide/formoterol inhalations 
twice daily versus one inhalation twice daily in smokers, but not in non smokers. These 
findings suggested that the budesonide/formoterol maintenance dose 200/6 two puffs 
twice a day is the preferred maintenance dose for smokers.  
 
Our primary outcome was the number of participants with at least one severe 
exacerbation, defined in accordance with the ATS/ERS Task Force criteria.20 The 
SMART regimen reduced the odds of a severe exacerbation by about 50%, with 
adjustment for smoking status, and with no significant interaction between smoking 
status and randomised treatment.  When adjusted for treatment regimen, smoking 
status had a significant effect on the number of severe exacerbations with ex smokers 
having a higher risk of severe exacerbations compared to never smokers. This 
suggests that the absolute reduction in the number of severe exacerbations with the 
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SMART regimen is greater in ex smokers because of their higher risk of this outcome 
compared with non smokers.   
 
An important and novel feature of the RCT was the use of electronic monitors in all 
MDIs to capture all actuations self-administered by participants in the study.18, 19 This 
builds on previous studies,14-16 by enabling an in-depth assessment of the relative 
safety of the SMART regimen including measures of beta-agonist overuse, delay in 
seeking medical assistance in worsening asthma and systemic corticosteroid 
exposure. There were similar proportions with at least one episode of high, marked 
and extreme overuse in the two treatment groups, however the SMART regimen led 
to a 40-50% reduction in the number of days of high, marked and extreme overuse 
episodes, with no significant interaction with smoking status.  We observed that current 
and ex smokers had a two to six-fold greater rate of these overuse episodes than 
never smokers, suggesting that there will be greater absolute benefit for this outcome 
in smokers.  The SMART regimen also reduced the risk of delay in seeking medical 
review during worsening asthma, with no significant interaction with smoking.   
 
The pattern of ICS use is of interest due to the reduced sensitivity to the effects of ICS 
therapy in smokers.8-13 Interestingly, with electronic monitoring, we observed that 
current smokers were less likely to take their ICS than never smokers during the period 
of the study.  The number of days of no ICS use was reduced with the SMART 
regimen, with no significant interaction between smoking status and treatment.   
 
Overall the findings were similar to those in Māori, a disadvantaged high risk group in 
New Zealand with substantive morbidity from asthma,27 in whom the relative benefits 
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of the SMART regimen were comparable to non-Māori.28 Together the findings 
suggest that the SMART regimen may not only be preferred in a general high risk 
population, as recruited in this study, but also specific very high risk groups within this 
population such as Māori and smokers. 
 
This analysis addresses secondary hypotheses from a RCT and thus, despite our 
finding of no interaction between smoking and randomised treatment, will have been 
at risk of Type I error rate inflation. As for most interaction analyses in RCTs the study 
was designed with statistical power to detect a difference in the whole group of 
participants. For some of the outcome variables there were low numbers of events in 
the smoking categories, limiting the ability to detect a moderate or weak effect of 
smoking status.  We are confident that participants with COPD did not enter the RCT 
because we excluded those with an active diagnosis of COPD, and current or ex 
smokers who had the onset of respiratory symptoms after the age of 40 and a >10 
pack year smoking history.   
 
In conclusion the favourable efficacy/safety profile of the SMART regimen, when 
compared to the standard maintenance ICS/LABA and SABA reliever therapy regimen 
in this high risk population, also applies to current and ex smokers.  Due to the higher 
baseline risk of morbidity and at risk behaviour in current and ex smokers, the absolute 
reduction in risk with the SMART regimen is greater in these patients.  We recommend 
the use of the SMART regimen in current and ex smokers with asthma. 
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Table 1. Characteristics of trial participants 
 Current Smoker Ex smoker Never Smoker 
 Smart Standard Smart Standard Smart Standard 
 N=30 N=29 N=49 N=48 N=72 N=75 
Age, years 
Mean (SD) 
39.8 
(11.5) 
39.0 
(12.6) 
44.3 
(12.7) 
45.1 
(14.4) 
39.9 
(14.9) 
42.4  
(15.2) 
Male, no (%) 
 
13 
(43.3) 
8  
(27.6) 
10 
(20.4) 
13  
(27.1) 
25  
(34.7) 
25  
(33.3) 
Duration of 
asthma, years, 
mean (SD) 
28.8 
(12.2) 
24.9 
(11.9) 
30.1 
(14.5) 
24.3 
(14.2) 
23.6 
(14.8) 
27.8  
(15.8) 
ACQ-7 Score 
Mean (SD) 
 
2.4  
(0.9) 
2.8  
(1.2) 
1.9  
(1.1) 
1.7  
(1.1) 
1.6  
(0.9) 
1.6  
(0.9) 
ACQ Band, no (%)       
≤ 0.75 1  
(3.3) 
1  
(3.5) 
7  
(14.3) 
9  
(18.8) 
12  
(16.7) 
14  
(18.7) 
0.75 to 1.5 2  
(6.7) 
2  
(6.9) 
13 
(26.5) 
14  
(29.2) 
19  
(26.4) 
23  
(30.7) 
 ≥1.5 27 
(90.0) 
26  
(89.7) 
29 
(59.2) 
25  
(52.1) 
41  
(56.9) 
38  
(50.7) 
Baseline FEV1 
Mean (SD) 
2.72 
(1.10) 
2.42 
(0.67) 
2.35 
(0.69) 
2.50 
(0.86) 
2.77 
(0.92) 
2.53  
(0.77) 
Baseline FEV1 % 
predicted, %, 
Mean (SD) 
79.2 
(18.1) 
76.5 
(20.8) 
79.3 
(20.7) 
81.5 
(19.3) 
84.2 
(17.9) 
81.2  
(21.2) 
Severe 
exacerbation in 12 
months before 
recruitment, no (%) 
26 
(86.7) 
25 
(86.2) 
46 
(93.9) 
47 
(97.9) 
65 
(90.3) 
69 
(92) 
ICS dose, mcg of 
budesonide 
equivalent,  Mean 
(SD) 
819 
(411) 
808  
(320) 
820 
(309) 
839  
(372) 
788  
(359) 
797  
(391) 
LABA use, no (%) 
 
18 
(60.0) 
19  
(65.5) 
34 
(69.4) 
34  
(70.8) 
40  
(55.6) 
50  
(66.7) 
Spacer use, no 
(%) 
 
14 
(46.7) 
14  
(48.3) 
31 
(54.4) 
26  
(54.2) 
30  
(41.7) 
35  
(46.7) 
Pre-study use of a 
written asthma 
self-management 
plan, no (%) 
1  
(3.3) 
 
3  
(10.4) 
10 
(20.4) 
7  
(14.6) 
4  
(5.6) 
10  
(13.3) 
Māori, no (%) 
 
8  
(26.7) 
7  
(24.1) 
11 
(22.5) 
7  
(14.6) 
6  
(8.3) 
5  
(6.7) 
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Pack year   history 
Median (range) 
7  
(1 to 40) 
9  
(0.3 to 
44) 
5 
(0.2 to 
34) 
4 
(1 to 60) 
0 
(0 to 0) 
0 
(0 to 0) 
ICS dose conversion: 500mcg fluticasone = 800mcg budesonide, 1000mcg 
beclomethasone = 800mcg budesonide. 
 ACQ: Asthma control questionnaire, FEV1: forced expiratory volume in 1 second, ICS: 
inhaled corticosteroid, LABA: long acting beta-agonist, no: number, SD: standard 
deviation 
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Table 2. Severe asthma exacerbations, corticosteroid exposure and efficacy outcomes in the SMART and Standard 
groups and interaction with smoking status 
 
Outcome 
Current smoker Ex smoker Never smoker 
SMART 
Versus 
Standard 
(adjusted for 
smoking status) 
Interaction term for 
effect of smoking 
on response to 
SMART vs 
Standard 
SMART 
N=30 
Standard 
N=29 
SMART 
N=49 
Standard 
N=48 
SMART 
N=72 
Standard 
N=75 
Participants with at least 
one severe 
exacerbation, no. (%) 
2 (6.7) 8 (27.6) 13 (26.5) 24 (50.0) 13 (18.1) 18 (24.0) 0.45 (0.26 to 0.77)* 
P= 0.004 
0.29 
Number of severe 
exacerbations, weighted 
mean rate per year (SD) 
0.14  
(0.55) 
0.94  
(1.79) 
1.02  
(2.41) 
1.39  
(1.58) 
0.46 
(1.12) 
0.67 
(1.35) 
0.55 (0.37 to 0.81)†   
P= 0.002 
0.11 
Participants with at least 
one hospital admission 
or ED attendance 
0 (0) 2 (6.9) 4 (8.2) 6 (12.5) 3 (4.2) 1 (1.3) 0.76 (0.27 to 2.11)* 
P=0.59 
0.48 
Daily budesonide dose, 
mcg, mean (SD) 
1598  
(3159) 
742  
(616) 
930  
(693) 
702  
(314) 
680  
(304) 
650 
(319) 
1.22 (1.06 to 1.41)‡ 
P= 0.006 
0.085 
Number of courses of 
oral corticosteroids per 
year of follow-up, mean 
(SD) 
0.29  
(1.25) 
0.94  
(1.79) 
1.45  
(3.88) 
1.81  
(2.30) 
0.57  
(1.48) 
0.79  
(1.55) 
0.59 (0.41 to 0.85)† 
P= 0.004 
0.47 
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Composite systemic 
corticosteroid exposure, 
mg prednisone 
equivalent per year,§ 
mean (SD) 
812  
(527) 
725  
(579) 
1047  
(1346) 
1048  
(1715) 
617 
(535) 
611 
(470) 
1.03 (0.87 to 1.22) ‡ 
P= 0.76 
0.62 
FEV1 at final visit, Litres, 
mean (SD) 
2.92 (1.17) 
(N=24) 
2.67 (0.92) 
(N=29) 
2.53 (0.67) 
(N=41) 
2.67 (0.98) 
(N=45) 
2.93 (0.92) 
(N=68) 
2.60 (0.91) 
(N=67) 
0.04 (-0.06 to 0.14) 
P=0.43 
0.63 
ACQ 7 Score at final visit, 
mean (SD) 
1.10 (0.73) 
(N=25) 
1.75 (1.40) 
(N=29) 
1.03 (0.90) 
(N=42) 
1.15 (0.92) 
(N=46) 
1.02 (0.70) 
(N=68) 
1.21 (1.0) 
(N=67) 
-0.23(-0.43 to -0.32) 
P=0.023 
0.43 
 
Data summaries are presented as number (percentage) or mean (standard deviation). Odds ratios,* relative rates† and ratio of means‡ 
are reported with 95% confidence intervals. The weighted mean rate per year is the total number of events in the study group/total 
person follow-up time in years for the study group. Relative rates were calculated by Poisson regression with an offset of the logarithm 
of the period of observation (for the analyses of severe exacerbation and number of courses of systemic corticosteroid), unless 
otherwise stated.   
 
N values are as per column headings unless otherwise stated. 
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§ Corticosteroid conversion: 100mg intravenous hydrocortisone = 25mg oral prednisone. Budesonide dose was converted to 
prednisone equivalent dose, based on a bioequivalence conversion calculated in a prior study (5000mcg budesonide=10mg 
prednisone).25 The sum of the prednisone equivalent dose and systemic corticosteroid dose was annualised. The logarithm of the 
annualised steroid use was the response variable in a weighted normal linear model, with the randomised treatment as a predictor 
and the treatment exposure time as a weight (individuals with longer periods of treatment exposure were given more weight and 
those with shorter periods of treatment exposure less weight in the analysis).  
 
Abbreviations: no.: number, SD: Standard deviation. 
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Table 3. Medication use outcomes in the SMART and Standard groups and interaction with smoking status 
 
Outcome 
 
Current smoker 
 
 
Ex smoker 
 
 
Never smoker 
SMART 
Versus 
Standard 
(adjusted for 
smoking status) 
Interaction term for 
effect of smoking on 
response to SMART 
vs Standard 
SMART 
(n=30) 
Standard 
(n=29) 
SMART 
(n=49) 
Standard 
(n=48) 
SMART 
(n=72) 
Standard 
(n=75) 
High beta-agonist use   
         
At least one episode of 
high beta-agonist use, no. 
(%) 
21 (70.0) 18 (62.1) 34 (69.4) 21 (43.8) 29(40.3) 29 (38.7) 1.56 (0.98 to 2.48)* 
P= 0.061 
 
0.18 
         
Number of days of high 
use 
9.7 
(15.7) 
18.7 
(34.1) 
7.2 
(20.8) 
8.5 (18.2) 1.7 (3.5) 5.4 (13.5) 0.59 (0.37 to 0.87)† 
P= 0.007 
0.11 
Number of days of high 
use without medical 
review in participants 
with at least one high 
use episode  
 
13.2 
(17.2) 
n=21 
28.2 
(35.6) 
n=18 
9.6 
(23.7) 
n=34 
16.8 
(20.4) 
n=21 
3.8   
(4.4) 
n=29 
13.2 
(17.6) 
n=29 
0.48 (0.31 to 0.74)† 
P <0.001 
0.47 
Marked beta-agonist overuse   
         
At least one episode of 
marked overuse, no. (%) 
16 (53.3) 17 (58.6) 22 (44.9) 18 (37.5) 16(22.2) 21 (28.0) 0.93 (0.58 to 1.52)* 
P= 0.79 
0.53 
         
Number of days of 
marked overuse 
 
4.4 (7.6) 11.5 
(29.0) 
4.4 
(16.4) 
4.6 (9.7) 0.8 (2.3) 2.4 (7.1) 0.57 (0.37 to 0.87)† 
P= 0.01 
0.08 
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Extreme beta-agonist overuse   
         
At least one episode of 
extreme overuse, no. (%) 
12 (40.0) 16 (55.2) 17 (34.7) 14 (29.2) 12 (16.7) 10 (13.3) 1.02 (0.60 to 1.74)* 
P= 0.92 
 
0.37 
         
Number of days of 
extreme overuse 
2.5 (4.4) 8.2 (26.1) 2.6 
(10.9) 
2.4 (5.2) 0.5 (1.7) 1.1 (4.0) 0.56 (0.35 to 0.90)† 
P= 0.014 
 
0.055 
Underuse of maintenance budesonide/formoterol treatment   
         
At least one day of zero 
actuations, no. (%) 
 
23 (76.7) 25 (86.2) 37 (75.5) 44 (91.7) 60 (83.3) 57 (77.0) 0.77 (0.43 to 1.37)* 
P= 0.37 
0.07 
Number of days of zero 
actuations 
 
23.9 
(36.8) 
57.7 
(58.4) 
22.8 
(32.0) 
29.6 
(37.7) 
24.6 
(31.5) 
27.2 
(35.6) 
0.73 (0.56 to 0.96)† 
P= 0.021 
0.12 
At least one day of one or 
less actuation, no. (%) 
 
23 (76.7) 26 (89.7) 40 (81.6) 44 (91.7) 66 (91.7) 62 (83.8) 0.85 (0.44 to 1.64)* 
P= 0.62 
0.06 
Number of days with 
one or less actuations 
 
28.7 
(41.4) 
59.4 
(58.4) 
28.0 
(35.0) 
34.3 
(41.2) 
29.4 
(33.5) 
30.2 
(38.1) 
0.80 (0.62 to 1.03)† 
P= 0.087 
0.18 
Data summaries are mean (standard deviation) unless otherwise stated.  The weighted mean rate per year is the total number of 
events in the study group/total person follow-up time in years for the study group. 
 
N values are as per column headings unless otherwise stated. 
 
no.: number. 
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Odds ratios* and relative rates† are reported with 95% confidence intervals. Relative rates were calculated by Poisson regression 
with an offset of the logarithm of the period of observation.
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Table 4. Severe asthma exacerbations, corticosteroid exposure and efficacy 
outcomes by smoking status** 
 
Outcome 
Smoking status 
Current vs never Ex vs never 
Participants with at 
least one severe 
exacerbation* 
0.77 (0.35 to 1.71) 
P=0.52 
2.40 (1.34 to 4.29) 
P=0.003 
Number of severe 
exacerbations, 
(weighted mean rate 
per year)† 
0.99 (0.56 to 1.76) 
P= 0.97 
2.03 (1.35 to 3.05) 
<0.001 
Participants with at 
least one hospital 
admission or ED 
attendance* 
1.26 (0.22 to 7.08) 
P=0.79 
4.13 (1.26 to 13.6) 
P=0.02 
Daily budesonide 
dose, mcg‡ 
1.17 (0.97 to 1.41) 
P=0.10 
1.17 (0.99 to 1.37) 
P=0.06 
Number of courses of 
oral corticosteroids 
per year of follow-up† 
0.94 (0.54 to 1.65) 
P=0.84 
2.19 (1.49 to 3.22) 
P <0.001 
Composite systemic 
corticosteroid 
exposure, mg 
prednisone equivalent 
per year§ ‡ 
1.23 (0.98 to 1.55) 
P=0.07 
1.40 (1.15 to 1.70) 
P <0.001 
Smoking status was significantly associated with all outcome measures above, except 
daily budesonide dose. 
**Adjusted by treatment regimen (SMART vs Standard) 
Odds ratios,* relative rates† and ratio of means‡ are reported with 95% confidence 
intervals. The weighted mean rate per year is the total number of events in the study 
group/total person follow-up time in years for the study group. Relative rates were 
calculated by Poisson regression with an offset of the logarithm of the period of 
observation (for the analyses of severe exacerbation, hospital admission or ED 
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attendance and number of courses of systemic corticosteroid), unless otherwise 
stated.   
§ Corticosteroid conversion: 100mg intravenous hydrocortisone = 25mg oral 
prednisone. Budesonide dose was converted to prednisone equivalent dose, based 
on a bioequivalence conversion calculated in a prior study (5000mcg 
budesonide=10mg prednisone).25 The sum of the prednisone equivalent dose and 
systemic corticosteroid dose was annualised. The logarithm of the annualised steroid 
use was the response variable in a weighted normal linear model, with the randomised 
treatment as a predictor and the treatment exposure time as a weight (individuals with 
longer periods of treatment exposure were given more weight and those with shorter 
periods of treatment exposure less weight in the analysis).  
 
ED: Emergency Department, mcg: micrograms, no.: number. 
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Table 5. Medication use outcomes in the SMART and Standard groups by 
smoking status adjusted by treatment regimen (SMART vs Standard) 
 Smoking status 
Current vs never Ex vs never 
High use    
At least one episode of high 
use, no. (%)* 
3.00 (1.59 to 5.68) 
P <0.001 
2.01 (1.19 to 3.40) 
P=0.009 
Number of days of high 
use† 
 
3.83 (2.36 to 6.22) 
P <0.001 
2.21 (1.35 to 3.62) 
P=0.002 
Number of days of high 
use without medical review 
in participants with at least 
one high use episode† 
 
2.46 (1.47 to 4.13) 
P<0.001 
1.59 (0.92 to 2.72) 
P=0.088 
Marked overuse   
At least one episode of 
marked overuse, no. (%)* 
 
3.78 (2.00 to 7.13) 
P <0.001) 
2.09 (1.21 to 3.62) 
P=0.009 
Number of days of marked 
overuse† 
 
4.76 (2.72 to 8.32)  
P <0.001 
2.81 (1.60 to 4.95) 
P <0.001 
Extreme overuse   
At least one episode of 
extreme overuse, no. (%)* 
5.13 (2.59 to 10.2) 
P <0.001 
2.67 (1.43 to 4.97) 
P=0.002 
 
Number of days of extreme 
overuse† 
6.17 (3.33 to 11.4) 
P<0.001 
2.99 (1.58 to 5.69) 
P <0.001 
Underuse of maintenance 
budesonide/formoterol 
  
At least one day of zero 
actuations, no. (%)* 
 
1.09 (0.50 to 2.35) 
P=0.83 
1.26 (0.64 to 2.47) 
P=0.50 
Number of days of no 
actuations† 
 
1.53 (1.11 to 2.12) 
P=0.01 
1.02 (0.74 to 1.40) 
P=0.90 
At least one day of one or less 
actuation, no. (%)* 
 
0.69 (0.44 to 1.64) 
P=0.39 
0.91 (0.42 to 1.96) 
P=0.81 
Number of days with one 
or less actuations† 
 
1.44 (1.05 to 1.97) 
P=0.024 
1.05 (0.78 to 1.42) 
P=0.74 
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Smoking status was not significantly associated with at least one day of zero actuations, at 
least one day of one or less actuations and number of days with one or less actuations.  
Smoking status was significantly associated all other outcome measures above. 
 
Odds ratios* and relative rates† are reported with 95% confidence intervals. The weighted 
mean rate per year is the total number of events in the study group/total person follow-up time 
in years for the study group. Relative rates were calculated by Poisson regression with an 
offset of the logarithm of the period of observation.  
 
no.: number. 
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Figure 1: Flow of participants through the study 
